China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+ financing round led by Yuanbio Venture Capital. The proceeds will be used to advance clinical studies for tumor immunotherapies and develop pipeline candidates based on its unique biomaterial technology platform.
Company Background
Founded in 2019, InnoBM Pharmaceuticals is an innovative drug research and development company focusing on the platformization of biomaterial technology. The company’s founder, Dr. Liu Zhuang, an expert in the biomaterial field, is engaged in cutting-edge interdisciplinary research on tumor microenvironment regulation and biomaterial delivery across biological barriers.-Fineline Info & Tech
